|
|
|
|
|
|
Sponsored by: |
Pfizer |
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00647829 |
The study was performed to evaluate the analgesic efficacy, safety, and tolerability of valdecoxib 20 mg twice daily (BID), valdecoxib 40 mg once daily (QD), and placebo in patients with moderately to severely painful symptomatic sore throat over a 24-hour period. In addition, the study was to validate a new scale and criteria for measuring pain in sore throat and evaluate the effects of selective serotonin reuptake inhibitors and past sore throat pain on pain score and efficacy of analgesics. The study also examined what type of medications are commonly used for sore throat and whether this information has relevance to analgesic efficacy.
Condition | Intervention | Phase |
Pharyngitis |
Drug: valdecoxib Drug: placebo |
Phase III |
MedlinePlus related topics: | Sore Throat |
ChemIDplus related topics: | Valdecoxib |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Clinical Protocol For A Double-Blind, Randomized, Placebo-Controlled Comparison Of The Efficacy, Safety, And Tolerability Of Bextra® (Valdecoxib) 20 Mg Twice Daily, Bextra® 40 Mg Once Daily, And Placebo In The Symptomatic Treatment Of Subjects With Pharyngitis |
Enrollment: | 197 |
Study Start Date: | February 2003 |
Study Completion Date: | December 2003 |
Arms | Assigned Interventions |
Arm 1: Active Comparator |
Drug: valdecoxib
valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
|
Arm 2: Active Comparator |
Drug: valdecoxib
valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
|
Arm 3: Placebo Comparator |
Drug: placebo
placebo tablet by mouth for 2 doses over a 24-hour period
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Connecticut | |||||
Pfizer Investigational Site | |||||
STORRS, Connecticut, United States, 06269-2011 | |||||
United States, Florida | |||||
Pfizer Investigational Site | |||||
BOCA RATON, Florida, United States, 33433 |
Pfizer |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
To obtain contact information for a study center near you, click here. 
  |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A3471026 |
First Received: | March 27, 2008 |
Last Updated: | April 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00647829 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|